by Portfolio Grader | November 6, 2013 11:15 am
This week, six Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
This is a strong week for Prana Biotechnology Ltd Sponsored ADR (NASDAQ:PRAN). The company’s rating climbs to B from the previous week’s C. Prana Biotechnology is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. For more information, get Portfolio Grader’s complete analysis of PRAN stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This week, Array BioPharma (NASDAQ:ARRY) pushes up from a C to a B rating. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Incorporated (NASDAQ:INSM) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Shares of INSM have increased 20.2% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/11/6-biotechnology-stocks-to-buy-now-aria-pran-nbix/
Short URL: http://invstplc.com/1nuS1H4
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.